A $1B Acquisition Gives Novartis a Way to Stand Out in Crowded Area of Cancer
Frank Vinluan / medcitynews - Myricx Bio brings to Novartis antibody drug conjugates with a novel cancer-killing payload called an NMT inhibitor. Novartis says Myricx’s drugs could have advantages over currently available ADCs as well as those still in clinical development. The post A…
AI Summary: Novartis has struck a roughly $1 billion deal to acquire Myricx Bio, a preclinical bet aimed at securing a novel antibody‑drug conjugate payload. The move is a clear attempt to stand out in a crowded oncology market by buying potential innovation rather than inventing it in‑house — or, as finance folks call it, buying optionality.
Related Stories
UCB acquires Candid for $2B to pursue T‑cell engager therapies / 2 months
Novartis pays $2B for Synnovation’s next‑gen PI3Kα inhibitor / 3 months
Gilead acquires Tubulis in multibillion-dollar push beyond HIV / 3 months
Merck to acquire Terns Therapeutics for $6.7B / 3 months
Servier to acquire Day One Biopharma for $2.5B / 4 months
Mass spectrometry platform could cut drug discovery to hours / 20 days
Engineered CAR‑T cells secreting VEGF‑neutralizing scFvs boost solid‑tumor activity / 4 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Food Safety, Wildlife, Diagnostics, Zoonotic Disease and look for the RSS link.
StackHealth Time Machine